{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:01Z","timestamp":1787671861873,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.109865","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:49:29Z","timestamp":1772178569000},"page":"109865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Gaucher disease therapy for Saposin C deficiency: Proof-of-concept with eliglustat"],"prefix":"10.1016","volume":"148","author":[{"given":"Carmen","family":"Minea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Deegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ymgme.2026.109865_bb0005","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","article-title":"Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting","volume":"19","author":"Vaccaro","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2026.109865_bb0010","unstructured":"O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders, FASEB J."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109865_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"Tamargo","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109865_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"IJMS"},{"issue":"5","key":"10.1016\/j.ymgme.2026.109865_bb0025","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic Gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J of Inher Metab Disea"},{"issue":"2","key":"10.1016\/j.ymgme.2026.109865_bb0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","article-title":"The risk of Parkinson\u2019s disease in type 1 Gaucher disease","volume":"33","author":"Bultron","year":"2010","journal-title":"J of Inher Metab Disea"},{"issue":"10","key":"10.1016\/j.ymgme.2026.109865_bb0035","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ymgme.2026.109865_bb0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109865_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/genes13040662","article-title":"Phenotype expansion for atypical Gaucher disease due to homozygous missense PSAP variant in a large consanguineous Pakistani family","volume":"13","author":"Liaqat","year":"2022","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.ymgme.2026.109865_bb0050","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s12031-022-01987-y","article-title":"A type 3 Gaucher-like disease due to saposin C deficiency in two Emirati families caused by a novel splice site variant in the PSAP gene","volume":"72","author":"Mohamed","year":"2022","journal-title":"J. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.ymgme.2026.109865_bb0055","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1399-0004.2007.00899.x","article-title":"Non-neuronopathic Gaucher disease due to saposin C deficiency","volume":"72","author":"Tylki-Szyma\u0144ska","year":"2007","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109865_bb0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","article-title":"Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1","volume":"17","author":"Dardis","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109865_bb0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109865_bb0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ymgme.2011.09.010","article-title":"Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form \u2014 no positive effects after 2-years of miglustat therapy","volume":"104","author":"Tylki-Szyma\u0144ska","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109865_bb0075","series-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci","first-page":"915","article-title":"Enzyme replacement therapy: conception, chaos and culmination","volume":"358","author":"Brady","year":"2003"},{"issue":"3","key":"10.1016\/j.ymgme.2026.109865_bb0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"KA","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2026.109865_bb0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N -butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J of Inher Metab Disea"},{"issue":"3","key":"10.1016\/j.ymgme.2026.109865_bb0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/pds.3760","article-title":"Results from a 9-year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca\u00ae)-treated patients","volume":"24","author":"Brand","year":"2015","journal-title":"Pharmacoepidemiology and Drug"},{"issue":"20","key":"10.1016\/j.ymgme.2026.109865_bb0095","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ymgme.2026.109865_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"S1","key":"10.1016\/j.ymgme.2026.109865_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10545-004-0001-x","article-title":"Abstracts - SSIEM 42st annual symposium, Paris, France, 6\u20139 September, 2005","volume":"28","author":"Editorial Board","year":"2005","journal-title":"J of Inher Metab Disea"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109865_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-5793(91)80760-Z","article-title":"Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease","volume":"284","author":"Schnabel","year":"1991","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.ymgme.2026.109865_bb0115","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","article-title":"Identification of modifier genes in a mouse model of Gaucher disease","volume":"16","author":"Klein","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109865_bb0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bcmd.2010.10.007","article-title":"A monozygotic twin pair with highly discordant Gaucher phenotypes","volume":"46","author":"Biegstraaten","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109865_bb0125","first-page":"7","article-title":"Gaucher disease: new expanded classification emphasizing neurological features","volume":"13","author":"Alaei","year":"2019","journal-title":"Iran. J. Child. Neurol."},{"issue":"12","key":"10.1016\/j.ymgme.2026.109865_bb0130","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.3390\/ijms25126615","article-title":"Deficiency of glucocerebrosidase activity beyond Gaucher disease: PSAP and LIMP-2 dysfunctions","volume":"25","author":"Pavan","year":"2024","journal-title":"IJMS"},{"issue":"2","key":"10.1016\/j.ymgme.2026.109865_bb0135","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.ymgme.2026.109865_bb0140","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s12325-024-02881-2","article-title":"Qualitative study of the patient experience with venglustat for Gaucher disease type 3 in a phase 2 open-label, multicenter, multinational study (LEAP)","volume":"41","author":"Schiffmann","year":"2024","journal-title":"Adv. Ther."},{"issue":"19","key":"10.1016\/j.ymgme.2026.109865_bb0145","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/BF01716064","article-title":"Activator protein deficient Gaucher\u2019s disease: a second patient with the newly identified lipid storage disorder","volume":"67","author":"Christomanou","year":"1989","journal-title":"Klin. Wochenschr."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109865_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01233949","article-title":"Mutational analysis in a patient with a variant form of Gaucher disease caused by SAP-2 deficiency","volume":"19","author":"Rafi","year":"1993","journal-title":"Somat. Cell Mol. Genet."},{"issue":"2\u20133","key":"10.1016\/j.ymgme.2026.109865_bb0155","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00439-005-1288-x","article-title":"A mutation within the saposin D domain in a Gaucher disease patient with normal glucocerebrosidase activity","volume":"117","author":"Diaz-Font","year":"2005","journal-title":"Hum Genet [Internet]."},{"key":"10.1016\/j.ymgme.2026.109865_bb0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bcmd.2017.04.001","article-title":"A rare form of Gaucher disease resulting from saposin C deficiency","volume":"68","author":"Kang","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109865_bb0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/epd2.20204","article-title":"A genetic cause for intractable seizures: atypical Gaucher disease with a novel pathological variant","volume":"26","author":"\u00dc\u00e7em","year":"2024","journal-title":"Epileptic Disorders [Internet]."},{"issue":"02","key":"10.1016\/j.ymgme.2026.109865_bb0170","doi-asserted-by":"crossref","first-page":"081","DOI":"10.1055\/s-0038-1675372","article-title":"Acute Gaucher disease-like condition in an Indian infant with a novel biallelic mutation in the prosaposin gene","volume":"08","author":"Radha Rama Devi","year":"2019","journal-title":"J. Pediatr. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:00:56Z","timestamp":1787670056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226001484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226001484"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109865","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing Gaucher disease therapy for Saposin C deficiency: Proof-of-concept with eliglustat","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109865"}}